Leif Bergsagel, MD, Mayo Clinic, Phoenix, AZ, and Francesco Maura, MD, Sylvester Comprehensive Cancer Center, discuss genomics of high-risk and smoldering multiple myeloma. Topics cover next-generation sequencing (NGS), del(17p) and TP53 mutations, high-risk factors, controversy surrounding 17P deletion and TP53 mutation, challenges in determining and targeting cancer cells.

Gareth Morgan, Rafael Fonseca, Leif Bergsagel, and Keith Stewart discuss highlights from day two of the Myeloma 2022 meeting, covering topics such as BCL2 inhibitors, T-cell exhaustion, immunotherapy, targeted therapies, combination therapies, minimal residual disease, and the efficacy of Carti therapy in managing melon.

Guests Gareth Morgan, Nina Shah, and Leif Bergsagel discuss the highlights of Myeloma 2017, including MRD's impact on clinical trials, promising results of nelfinavir and proteasome inhibitor combination therapy, advancements in targeted therapies and imaging, and the consensus on primary principles of MM treatment.